We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 11. | 장 마감 후 (AMC) | — | — | — | $9.38M | — | 예정 |
Consensus PT $7.6 · 5 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 28. | Barclays | — | 커버리지 개시 | — → Overweight | — | Barclays: Overweight |
| 2026. 04. 14. | Citizens | — | 의견 유지 | Market Outperform → Market Outperform | — | Citizens: Market Outperform |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 27,314 | $132.2M | 0.00% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Stored first · Google News · Yahoo Finance (English)
Cellectis S A : Report of the Board of Directors - Combined General Meeting of Shareholders - June 25, 2026 - marketscreener.com
Cellectis S A : Report of the Board of Directors - Combined General Meeting of Shareholders - June 25, 2026 marketscreener.com
CLLS Initiated Coverage By Barclays -- Rating Set to Overweight - GuruFocus
CLLS Initiated Coverage By Barclays -- Rating Set to Overweight GuruFocus
Barclays initiates coverage of Cellectis SA - depositary receipt (CLLS) with overweight recommendation - MSN
Barclays initiates coverage of Cellectis SA - depositary receipt (CLLS) with overweight recommendation MSN
Cellectis (CLLS) Stock Dips 1.27% as Biotech Volatility Persists; Key Support at $3.32 in Focus - Dark Pool Prints - thelegaladvocate.com
Cellectis (CLLS) Stock Dips 1.27% as Biotech Volatility Persists; Key Support at $3.32 in Focus - Dark Pool Prints thelegaladvocate.com
Cellectis (CLLS) Slides 1.27% as Biotech Struggles to Hold Above Key Support - ADD Alert - thelegaladvocate.com
Cellectis (CLLS) Slides 1.27% as Biotech Struggles to Hold Above Key Support - ADD Alert thelegaladvocate.com
[Latest] Global Genome Editing Market Size/Share Worth USD 55.7 Billion by 2035 at a 17.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)